Clinical trial
Imatinib Mesylate in Treating Patients With Gliomas
NCT00039364 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00039364 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With Gliomas |
| Official title | Open Label Phase II Study On STI571 (Glivec) Administered As A Daily Oral Treatment In Gliomas |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | imatinib mesylate |
| Enrollment | 112 |
| Start date | Mar 1, 2002 |
| Primary completion | Aug 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 24, 2012 |
| Countries | Austria, Belgium, France, Italy, Netherlands, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: